Mineralys Q2 2026: $241M Net Loss Driven by $200M IP Buyout; Cash Runway at $661M Ahead of December PDUFA
MLYS has more than doubled off its 52-week low of $12.59.
Summary
Mineralys Therapeutics posted a $241.1M Q2 net loss after a $200M IP buyout, raised $143.6M in equity and $100M in debt, and holds $661.4M in cash ahead of a December 2026 FDA decision on lorundrostat.
Key Events · Earnings and Guidance · MLYS
-
Q2 Net Loss of $241.1M
Net loss widened to $241.1M from $43.3M in Q2 2025, primarily due to a $200M upfront payment to Tanabe Pharma for royalty-free, perpetual IP rights to lorundrostat.
-
$200M IP Buyout Reshapes Royalty Obligations
The Fourth Amendment to the Tanabe License eliminated future royalties on lorundrostat sales in exchange for a $200M upfront payment and up to $255M in commercial milestones, recognized as R&D expense.
-
Capital Raises Bolster Cash to $661.4M
Raised $143.6M net from a public offering of 5.66M shares at $26.50 and $20.2M net from ATM sales at a weighted-average $35.66; drew $100M Tranche A of a $500M term loan at 9.15% interest.
-
Cash Runway Extends Through Launch
Ended Q2 with $661.4M in cash, equivalents, and investments, which management believes funds operations including the commercial launch of lorundrostat for at least 12 months.
Analysis · MLYS · Life Sciences
A $200 million upfront payment to Tanabe Pharma for royalty-free, perpetual rights to lorundrostat drove Mineralys Therapeutics to a $241.1 million net loss in Q2 2026. To fortify its balance sheet, the company raised $143.6 million in a public offering at $26.50 per share and drew $100 million from a new senior secured term loan, ending the quarter with $661.4 million in cash and investments. With a PDUFA date of December 22, 2026 for lorundrostat in hypertension, the company is positioned for a potential commercial launch, though the substantial cash burn and dilutive financing underscore the capital intensity of this pre-revenue biotech.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $26.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $12.59 to $47.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.